Otitis Media and URI without MCC DRG Reimbursement Guide

DRG 153 includes inpatient encounters for otitis media and upper respiratory infection without Major Complication or Comorbidity, representing lower-severity ear and upper airway infections. This classification matters for inpatient reimbursement because it affects the bundled payment level from the Centers for Medicare & Medicaid Services and reflects the absence of higher-severity complicating conditions.

DRG 153 Overview

DRG 153 covers inpatient admissions for otitis media and upper respiratory infections without Major Complication or Comorbidity. This Diagnosis-Related Group captures relatively lower-severity infectious conditions of the ear and upper airway that do not trigger higher-severity payment adjustments. It matters for Medicare payment because cases classified here typically receive lower bundled reimbursement than similar diagnoses with complications or comorbid conditions. Accurate coding and documentation determine whether an admission is assigned to this Diagnosis-Related Group versus a higher-paying group.

Acute antimicrobial stewardship and short-course versus standard-course antibiotic trials: randomized studies testing shorter-duration antibiotic regimens, rapid diagnostic-guided prescribing, or watchful waiting protocols for pediatric and adult patients hospitalized with acute otitis media or upper respiratory infections without major complications. These trials focus on the immediate inpatient management phase, enrolling patients admitted for symptomatic control and suspected bacterial infection to evaluate clinical cure, symptom duration, and readmission rates. Results inform providers and payers by identifying safe strategies to reduce antibiotic use, length of stay, and drug costs while maintaining quality of care and avoiding downstream complications.
Comparative effectiveness studies of symptomatic and supportive therapies in the emergency-to-inpatient transition: pragmatic trials comparing analgesic strategies, intranasal therapies, or non-antibiotic supportive care bundles (including hydration, decongestants where appropriate, and observation protocols) among children and adults admitted for otitis media or URI symptoms. These studies enroll typical DRG 153 patients to assess pain control, functional recovery, and resource utilization (eg, need for ancillary services, return visits). Findings help hospitals and payers optimize inpatient care pathways that balance patient comfort, avoid unnecessary interventions, and reduce overall hospitalization costs.
Post-discharge outcome and health services research evaluating readmissions, antibiotic stewardship adherence, and outpatient follow-up patterns: cohort or registry studies tracking patients after discharge to measure rates of return ED visits, subsequent antibiotic prescriptions, complications (such as progression to complicated sinusitis or mastoiditis), and adherence to recommended outpatient follow-up. These studies often stratify by age, comorbidity, and social determinants to identify high-risk subgroups and care gaps. The evidence guides care coordination programs, targeted case management, and payer policies aimed at reducing preventable readmissions and optimizing long-term resource allocation for this common DRG.

Acute antimicrobial stewardship and short-course versus standard-course antibiotic trials: randomized studies testing shorter-duration antibiotic regimens, rapid diagnostic-guided prescribing, or watchful waiting protocols for pediatric and adult patients hospitalized with acute otitis media or upper respiratory infections without major complications. These trials focus on the immediate inpatient management phase, enrolling patients admitted for symptomatic control and suspected bacterial infection to evaluate clinical cure, symptom duration, and readmission rates. Results inform providers and payers by identifying safe strategies to reduce antibiotic use, length of stay, and drug costs while maintaining quality of care and avoiding downstream complications.
Comparative effectiveness studies of symptomatic and supportive therapies in the emergency-to-inpatient transition: pragmatic trials comparing analgesic strategies, intranasal therapies, or non-antibiotic supportive care bundles (including hydration, decongestants where appropriate, and observation protocols) among children and adults admitted for otitis media or URI symptoms. These studies enroll typical DRG 153 patients to assess pain control, functional recovery, and resource utilization (eg, need for ancillary services, return visits). Findings help hospitals and payers optimize inpatient care pathways that balance patient comfort, avoid unnecessary interventions, and reduce overall hospitalization costs.
Post-discharge outcome and health services research evaluating readmissions, antibiotic stewardship adherence, and outpatient follow-up patterns: cohort or registry studies tracking patients after discharge to measure rates of return ED visits, subsequent antibiotic prescriptions, complications (such as progression to complicated sinusitis or mastoiditis), and adherence to recommended outpatient follow-up. These studies often stratify by age, comorbidity, and social determinants to identify high-risk subgroups and care gaps. The evidence guides care coordination programs, targeted case management, and payer policies aimed at reducing preventable readmissions and optimizing long-term resource allocation for this common DRG.

OpenPayer

Summary & Overview

Otitis Media and URI without MCC: Inpatient Reimbursement Overview

DRG 153 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes